BridgeMD
New treatment option for Hyperlipidemia; Mixed
Official title Study of ARO-DIMERPA in Adult Participants With Mixed Hyperlipidemia
ClinicalTrials.gov ID: NCT07223658
What this study is testing
What is ARO-DIMERPA?
ARO-DIMERPA is an investigational medicine, given as an injection under the skin, being studied as a potential treatment for hyperlipidemia; mixed.
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- Study to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD), and effects on low-density lipoprotein cholesterol (LDL-C) and triglycerides (TGs) of single-dose ARO-DIMERPA and multiple doses of ARO-DIMERPA in adult participants with mixed hyperlipidemia.
- Phase 2: a mid-size study of how well it works
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 and older
You may be able to join if
- Willing to follow diet counseling as per Investigator judgment based on local standard of care
- Specific fasting TG, LDL-C, and non-high density lipoprotein cholesterol levels at Screening
- Participants of childbearing potential must agree to use highly effective contraception in addition to a condom during the study and for at least 90...
You likely can't join if
- Current use or use within last 365 days or within 5-half-lives before Day 1 based on plasma PK, whichever is longer, of any hepatocyte-targeted siRNA
- Current use or use within last 90 days or within 5-half-lives before Day 1 based on plasma PK, whichever is longer, of any antisense oligonucleotide...
- Current use or use within last 60 days from Day 1 of any PCSK9 inhibitor monoclonal antibodies (eg, evolocumab or alirocumab)
- Uncontrolled hypertension
- History of bleeding diathesis or coagulopathy
- Current diagnosis of nephrotic syndrome Note: Additional inclusion/exclusion criteria may apply per protocol.
The study team makes the final eligibility decision.
Where it's taking place
- Charlestown, New South Wales, Australia
- Morayfield, Queensland, Australia
- East Melbourne, Victoria, Australia
- Melbourne, Victoria, Australia
- Perth, Western Australia, Australia
- Clayton, Australia
- Calgary, Canada
- Tbilisi, Georgia
- Grafton, Auckland, New Zealand
- Auckland, New Zealand
- Christchurch, New Zealand
- Wellington, New Zealand
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Charlestown, New South Wales, Australia; Morayfield, Queensland, Australia; East Melbourne, Victoria, Australia; Melbourne, Victoria, Australia; Perth, Western Australia, Australia; Clayton, Australia and 6 more location(s). Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.